Dolutegravir / Lamivudine Pill

DRUG2 trials

Sponsors

Charlotte-Paige Rolle, MD, Erasmus Medical Center

Conditions

HIV I InfectionHiv

Phase 4

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF

CompletedNCT04585737

Charlotte-Paige Rolle, MDHIV I Infection

Start: 2020-10-05End: 2023-08-10Updated: 2024-10-17

Unknown Phase

Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study

Active, not recruitingNCT04707326

Erasmus Medical CenterHiv

Start: 2019-11-01End: 2026-11-01Updated: 2024-12-20

Related Papers

P-348. Real-world efficacy, safety and persistence of dolutegravir/lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide among virologically suppressed adults with HIV-results from the 96-week observational extension phase of the DYAD study

Open Forum Infectious Diseases2026-01-01

Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study

Open Forum Infectious Diseases2024-03-18

1603. Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study

Open Forum Infectious Diseases2023-11-272 citations